In the phase III study,

In the phase III study, PR-171 molecular weight the incidence rate of ultrasound diagnosed intussusception was 581 per 100,000 child years (95% CI 332, 943) and

of Brighton level 1 intussusception was 254 per 100,000 child years (95% CI 102, 524) in children under active surveillance till 2 years of age. The rate of ultrasound diagnosed intussusception in the second half of the first year of life (738 child years of observation), which is considered the period of greatest risk, was 949 per 100,000 child years (95% CI 381, 1954) while that for intussusception meeting Brighton level 1 criteria was 406 per 100,000 child years (95% CI 83, 1188). The median age of intussusception in the surveillance cohort of 375 days (IQR 248–574) was significantly higher than Autophagy inhibitor that of children presenting from the general population where the median was

214 days (IQR 153–321 days) (p = 0.001). Cases of intussusception identified through active surveillance were significantly less likely to show evidence of obstruction and ischemia (Table 2) and therefore less likely to require surgical intervention as compared to those who routinely present to tertiary care pediatric surgery facilities with intussusception. This is supported by the fact that even among the intussusceptions that met Brighton level 1 criteria, none of those identified through active surveillance and 31 (50.8%) of those directly presenting to hospital required surgery. The global average for intussusception rates is estimated at 74 per 100,000 child years [17], with the highest rates being reported from Vietnam (287 and 302 per 100,000 in Ho Chi Minh City and Hanoi, respectively and Korea (328 per 100,000) [18], [19] and [20]. These rates were largely based on passive surveillance where cases were captured in hospitals from defined populations. With intensive, active surveillance, the incidence of intussusception meeting Brighton level 1 diagnostic certainty in 1500 children

in Vellore (254 per 100,000 children) was similar to the highest global rates, which while not using active surveillance also have a high rate of ultrasound use for diagnosis of intussusception [18]. When active surveillance using ADP ribosylation factor broad screening criteria such as those employed in the rotavirus phase III trial is undertaken, many potential cases might be identified that may not meet the criteria for level 1 diagnostic certainty of intussusception, as demonstrated by the finding of 16/444 positive ultrasonograms. Even among the positive ultrasonograms, a large number of transient intussusceptions of doubtful clinical significance are likely to be identified inflating the incidence of intussusception. Transient intussusception, especially within segments of the small bowel in the absence of a lead point, may be a coincidental finding and correlating it with the clinical condition and presentation is central to the clinical decision-making process.

Comments are closed.